ObsEva-Annual-Report-2017 (2)Download
Tag: 2017
ObsEva SA at BMO Healthcare Conference
Company management will be presenting at the BMO Prescriptions for Success Healthcare Conference Date & Time: Thursday 14 December 2017 at…
ObsEva SA to Participate in BMO Healthcare Conference December 14th 2017
Geneva, Switzerland and Boston, MA _ December 7, 2017 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company focused on the development and…
ObsEva Initiates PROLONG, the Phase 2a Clinical Trial of OBE022 in Preterm Labor
OBE022 is a first-in-class, oral and selective PGF2alpha receptor antagonist for the potential treatment of preterm labor to delay or…
ObsEva at Jefferies 2017 London Healthcare Conference
Company Management will be presenting and holding one-on-one meetings with investors at Jefferies 2017 London Healthcare Conference Date & Time: 15…
Q3 Report 2017
ObsEva Reports Third Quarter 2017 Financial Results and Provides Business Update
– All Three Development Compounds Progressing with Key Clinical Milestones Over the Next 12 Months – Geneva, Switzerland and Boston, MA – November 14,…
Q3 2017 ObsEva SA Earnings Conference call
ObsEva to report financial results and business update for the third quarter on Tuesday, November 14, 2017 Date & Time: 14…
ObsEva at Credit Suisse Healthcare Conference
Company Management will be presenting and holding one-on-one meetings with investors at Credit Suisse Healthcare Conference Date & Time: 8 November…
ObsEva SA Announces the Completion of Patient Recruitment in the EDELWEISS Phase 2b Clinical Trial of OBE2109 for the Treatment of Endometriosis
Geneva, Switzerland and Boston, MA – November 7, 2017 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for…